XSTO
IBTb
Market cap79mUSD
May 23, Last price
57.90SEK
1D
-0.52%
1Q
44.75%
Jan 2017
47.03%
IPO
4.95%
Name
Infant Bacterial Therapeutics AB
Chart & Performance
P/E
—
P/S
9,788.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.76%
Rev. gr., 5y
22.47%
Revenues
77k
+541.67%
Net income
-123m
L+89.06%
CFO
-113m
L+11.77%
Earnings
Aug 26, 2025
Profile
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 77 541.67% | 12 | ||||||||
Cost of revenue | 135,762 | 65,820 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (135,685) | (65,808) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (357) | |||||||||
Tax Rate | ||||||||||
NOPAT | (135,685) | (65,451) | ||||||||
Net income | (123,068) 89.06% | (65,094) 43.37% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 2,013 | 101,545 | 1,884 | |||||||
BB yield | -9.13% | -0.34% | ||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 8,746 | |||||||||
Net debt | (223,388) | (329,134) | (335,910) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (113,133) | (101,219) | (85,795) | |||||||
CAPEX | ||||||||||
Cash from investing activities | (4,146) | (1,000) | ||||||||
Cash from financing activities | 2,013 | 96,515 | 1,884 | |||||||
FCF | (135,685) | (65,451) | ||||||||
| Balance | ||||||||||
Cash | 223,388 | 329,064 | 335,840 | |||||||
Long term investments | 70 | 70 | ||||||||
Excess cash | 223,388 | 329,130 | 335,909 | |||||||
Stockholders' equity | (598,579) | (461,676) | (339,220) | |||||||
Invested Capital | 768,842 | 766,830 | 670,926 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 12,365 | 11,226 | ||||||||
Price | 53.60 -40.44% | 90.00 80.00% | 50.00 -25.15% | |||||||
Market cap | 1,112,815 98.25% | 561,309 -25.15% | ||||||||
EV | 783,681 | 225,399 | ||||||||
EBITDA | 816 | (134,869) | (64,992) | |||||||
EV/EBITDA | ||||||||||
Interest | 293 | |||||||||
Interest/NOPBT | ||||||||||